VISCHER Ltd advises BioTie Therapies Oyj, the listed Finland based Biopharmaceutical Company engaged in the discovery and development of drugs focused on central nervous system and inflammatory diseases, in its acquisition of Synosia Therapeutics Holding AG, the Switzerland based pharmaceutical company involved in the development of drugs in the area of psychiatry and neurology, from Aravis Venture, the Switzerland based private equity firm, for an equity consideration of EUR 93.6m. The VISCHER team includes Matthias Staehelin (Partner) and Stefan Grieder (Partner).